Company Analysis
Sign in

VistaGen Therapeutics, Inc. (VTGN)

Nasdaq: VTGN · Pharmaceutical Preparations · South San Francisco, CA · filing with the SEC since 2007
Full chart Alerts Compare
Grade4.8
◀ Past 2.9● Present 4.0▶ Future 6.6
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

14 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to VistaGen Therapeutics, Inc.’s names, not what it holds today.

Patents granted
14
14 utility, 1976 to Dec 31, 2025
Granted in 2025
none
in the last year the record reads
Applications published
22
3 of them in 2025
Names they are printed under
2
a subsidiary, its own name
By yearGrantedApplications published
'06'09'12'13'14'15'16'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Pherin Pharmaceuticals, Inc. a subsidiary
US, as the owner printed on each patent
14 granted
7 published
VISTAGEN THERAPEUTICS, INC. its own name
named as the applicant on its applications, in US
0 granted
15 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Aug 23, 202211,419,881Treatment of migrainePharmaceuticalsPherin Pharmaceuticals, Inc.
Jun 18, 201910,322,138Treatment of depressive disordersPharmaceuticalsPherin Pharmaceuticals, Inc.
May 13, 20148,722,652Acute treatment of social phobiaPharmaceuticalsPherin Pharmaceuticals, Inc.
Apr 30, 20138,431,559Treatment of hot flashesPharmaceuticalsPherin Pharmaceuticals, Inc.
Nov 13, 20128,309,539Acute treatment of social phobiaPharmaceuticalsPherin Pharmaceuticals, Inc.
Aug 8, 20067,087,430Human VNO cDNA librariesBiotechnologyPherin Pharmaceuticals, Inc.
Apr 29, 20036,555,531Weight promoting composition, method, and productPharmaceuticalsPherin Pharmaceuticals, Inc.
Apr 8, 20036,544,971Method of increasing alertness by administration of a vomeropherin, and vomeropherin-emitting alarm devicesPharmaceuticalsPherin Pharmaceuticals, Inc.
Mar 5, 20026,352,980Estrenes for inducting hypothalamic effectsOrganic fine chemistryPherin Pharmaceuticals, Inc.
Dec 18, 20016,331,534Steroids as neurochemical stimulators of the VNO to alleviate painOrganic fine chemistryPherin Pharmaceuticals, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Oct 9, 20252025/0312544INTRANASAL DRUG DELIVERY SYSTEMMedical technologyVISTAGEN THERAPEUTICS, INC.
Oct 9, 20252025/0312356TREATMENT OF DYSMENORRHEAPharmaceuticalsVISTAGEN THERAPEUTICS, INC.
May 22, 20252025/0161251DOSAGE FORMS AND THERAPEUTIC USES OF L-4-CHLOROKYNURENINEPharmaceuticalsVISTAGEN THERAPEUTICS, INC.
Apr 18, 20242024/0122887THERAPEUTIC USES OF L-4-CHLOROKYNURENINEPharmaceuticalsVISTAGEN THERAPEUTICS, INC.
Jul 6, 20232023/0210867TREATMENT OF ADJUSTMENT DISORDERSPharmaceuticalsVISTAGEN THERAPEUTICS, INC.
Jun 30, 20222022/0202756GENETIC VARIANTS ASSOCIATED WITH RESPONSE TO TREATMENT OF NEUROLOGICAL DISORDERSPharmaceuticalsVISTAGEN THERAPEUTICS, INC.
Sep 9, 20212021/0276942SYNTHESIS OF 4-CHLOROKYNURENINES AND INTERMEDIATESOrganic fine chemistryVISTAGEN THERAPEUTICS, INC. · patent 11,427,530 granted from it
Oct 15, 20202020/0323884Treatment of migrainePharmaceuticalsPherin Pharmaceuticals, Inc. · patent 11,419,881 granted from it
Oct 24, 20192019/0321317THERAPEUTIC USES OF L-4-CHLOROKYNURENINEPharmaceuticalsVISTAGEN THERAPEUTICS, INC.
May 2, 20192019/0125707DOSAGE FORMS AND THERAPEUTIC USES OF L-4-CHLOROKYNURENINEPharmaceuticalsVISTAGEN THERAPEUTICS, INC. · patent 10,632,091 granted from it
What it applied for, 2024 to 2025: Pharmaceuticals 3 · Medical technology 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton VTGN · research, not advice